Breaking Finance News

Trinity Biotech plc (ADR) (NASDAQ:TRIB) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.

Zacks Investment Research has upgraded Trinity Biotech plc (ADR)(NASDAQ:TRIB) to Hold in a report released on 8/20/2016.

On 7/29/2015, ROTH Capital reported on Trinity Biotech plc (ADR)(NASDAQ:TRIB) dropped the target price from $22.00 to $20.00 that suggested an upside of 0.00%.

Showing a price of $12.00, Trinity Biotech plc (ADR) (NASDAQ:TRIB) traded 0.90% lower on the day. With the last stock price close up 13.74% relative to the 200-day average, compared to the Standard & Poor’s 500 Index which has fallen -0.01% over the same time. TRIB has registered a 50-day moving average of $12.80 and 200-day average of $11.62. Trade volume was was up over the average, with 67,530 shares of TRIB changing hands over the typical 52,225 shares.

Recent Performance Graph:

Trinity Biotech plc (ADR) (NASDAQ:TRIB)

Trinity Biotech plc (ADR) has a one-year low of $9.20 and a 52 week high of $14.52 with a P/E ratio of 56. The company’s market capitalization is currently $0.0.

Brief Synopsis On Trinity Biotech plc (ADR) (NASDAQ:TRIB)

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine. It operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, and physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business. Trinity Biotech’s blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *